United States Patent 6,701,917: Scope, Claims, Expiration, and Inhaler Patent Landscape

U.S. Patent No. 6,701,917 protects mechanical dose-counting systems for medicament inhalers. Its core technology uses a rolled, indicia-bearing ribbon that advances from a bobbin onto a toothed spool. A pawl or cover-operated transmission rotates the spool as the inhaler meters a dose or as its cover opens and closes.

The patent is directed to inhaler architecture, not a particular active pharmaceutical ingredient. Its claims cover bulk dry-powder inhalers, dose-metering mechanisms, ribbon-based numerical counters, one-way spool rotation, transparent viewing windows, and cover-actuated counting systems. The ordinary 20-year patent term appears to have ended in 2020, subject to any patent-term adjustment or other statutory extension shown in the official USPTO record.

What does U.S. Patent 6,701,917 protect?

The patent protects two related inhaler configurations:

A dose-meter-actuated counter in which a pawl moves along a path and rotates a toothed spool.
A cover-actuated counter in which opening or closing the inhaler cover rotates the spool through cams, a yoke, and a pawl.

The protected counter has four central components:

Component	Claimed function
Bobbin	Supports the rolled ribbon
Ribbon	Carries sequential indicia, such as numbers
Rotatable spool	Receives the ribbon as it advances
Teeth and pawl	Convert inhaler movement into spool rotation

The ribbon begins with one end secured to the spool while the opposite end remains positioned on the bobbin. As the inhaler operates, the ribbon transfers onto the spool. The visible indicia therefore provide a progressive dose count.

The claims do not require a specific drug, formulation, propellant, particle size, inhaler resistance, or therapeutic indication. A device can fall within the claim language regardless of whether it delivers a corticosteroid, bronchodilator, anticholinergic, antibiotic, or other inhaled medicament.

How broad is independent claim 1?

Claim 1 is the principal dose-metering claim. It requires an inhaler comprising:

A mouthpiece;
A dose meter;
A pawl movable along a predetermined path;
A dose counter;
A bobbin;
A rotatable spool;
A rolled ribbon;
Indicia extending successively along the ribbon;
A first ribbon end secured to the spool;
A second ribbon end positioned on the bobbin; and
Radially outwardly extending spool teeth located in the pawl's path.

The claim is functionally linked. The pawl must engage the spool teeth so that the spool rotates and the ribbon advances when a dose is metered.

Claim 1 scope by limitation

Claim limitation	Scope and practical meaning
"Medicament inhaler"	Requires an inhalation device, not a general-purpose counter
"Mouthpiece"	Requires a patient-facing inhalation outlet
"Dose meter"	Requires a mechanism associated with measuring or dispensing a dose
"Pawl movable along a predetermined path"	Covers a projecting engagement member with defined movement
"Bobbin"	Supports the supply roll of ribbon
"Rotatable spool"	Receives and winds the ribbon
"Rolled ribbon"	Excludes rigid disks and most purely electronic counters
"Indicia"	Requires visible or otherwise carried information on the ribbon
"Teeth extending radially outwardly"	Requires spool teeth positioned for pawl engagement
"Ribbon advanced onto the spool"	Requires transfer of ribbon from the bobbin to the spool

The strongest limitation for validity and infringement analysis is the combination of a rolled ribbon and a spool with radially outward teeth directly engaged by a pawl associated with dose metering. A conventional rotary disk counter, electronic display, or counter driven by a gear train without the claimed ribbon arrangement would present a substantial non-infringement position.

What do dependent claims 2 through 11 add?

The dependent claims narrow the mechanism and its operating environment.

Claim	Added limitation	Commercial significance
2	Spool rotates in a single direction	Excludes counters permitting ordinary reverse movement
3	Clutch spring provides one-way rotation	Narrows the reverse-prevention mechanism
4	Indicia are numbers	Targets conventional numerical dose counters
5	Indicia face radially outward	Requires visibility on the exterior surface of the roll
6	Pawl path is linear	Excludes pawls moving only along a curved or rotary path
7	Pawl moves in first and second directions and engages during the second direction	Defines a reciprocating pawl cycle
8	Housing has a transparent window over the ribbon indicia	Covers direct visual dose-count display
9	Reservoir has a dispensing port connected to the mouthpiece through dose metering	Links the counter to a dispensing reservoir
10	Reservoir contains bulk dry powder	Targets reservoir-based dry-powder inhalers
11	Numbers successively decrease as ribbon advances	Covers countdown displays showing doses remaining

Claims 2, 3, and 14 address the risk of false counts caused by reverse spool movement. Claims 4, 5, 8, and 11 focus on the user-visible counter. Claims 9 and 10 narrow the invention toward bulk-reservoir dry-powder devices rather than pre-metered blister or capsule systems.

What does independent claim 12 protect?

Claim 12 is a separate independent apparatus claim. It does not require the dose-meter pawl arrangement in claim 1. Instead, it requires:

A housing with a case;
A mouthpiece;
A pivotally mounted cover;
A dose counter containing the bobbin, ribbon, spool, and teeth; and
Transmission means engaging the cover and spool teeth.

The spool must rotate when the cover moves from open to closed or from closed to open.

This claim can reach a cover-actuated counter even if the counter is not directly driven by the dose-metering mechanism. That distinction is commercially important. A device may avoid claim 1 by separating the dose-meter movement from the counter while still implicating claim 12 if opening or closing the cover rotates the toothed spool.

What do claims 13 and 14 add?

Claim 13 specifies the transmission architecture:

At least one cam;
A cam pivotally connected to the case and cover;
At least one yoke inside the case;
A cam follower on the yoke; and
A pawl extending from the yoke to engage the spool teeth.

Claim 14 requires reverse-rotation prevention. The claim is broad as to the specific mechanism used for that function. A clutch spring, ratchet, pawl geometry, friction element, or other structure could potentially satisfy the limitation depending on claim construction and the accused device.

What patent features create the principal infringement risks?

The highest-risk configurations are inhalers that combine the following elements:

A physical ribbon rather than an electronic display.
A supply roll on a bobbin.
A take-up spool with outward-facing teeth.
A pawl that directly engages those teeth.
A counter activated by dose-meter movement or cover movement.
A one-way clutch or other reverse-prevention structure.
A transparent window showing numerical indicia.

A device does not need to copy the exact external appearance of the patented inhaler. The claims are directed to internal mechanical relationships. Hidden components can support infringement if the required structure and operation are present.

How can an inhaler be designed around Patent 6,701,917?

Potential design-around strategies include:

Design-around approach	Claims primarily avoided
Use a rotary disk with printed numbers instead of a rolled ribbon	Claims 1-14
Use an electronic sensor and display	Claims 1-14
Use a flexible ribbon that remains stationary while a window moves	Claims requiring ribbon advancement onto the spool
Drive the counter with a gear, ratchet, or cam that does not have spool teeth in a pawl path	Claims 1 and 7
Use a dose counter independent of cover movement	Claim 12
Use a cover that does not actuate the counter	Claims 12-14
Use pre-metered blister strips with a separate counting system	Claims 9-10 and potentially the independent claims
Permit bidirectional spool movement or use an alternative anti-reverse mechanism	Claims 2, 3, and 14, though claim 1 may remain relevant

A design-around must be evaluated against every limitation of every potentially asserted claim. Removing the ribbon may avoid the central literal limitation, but a related patent family could protect a different counter structure.

When did U.S. Patent 6,701,917 expire?

The patent issued on March 2, 2004. Its ordinary patent term appears to have ended in 2020 based on the applicable 20-year term measured from the relevant U.S. or international filing date.

Event	Date or period
Patent issued	March 2, 2004
Ordinary patent term	Approximately 20 years from the relevant filing date
Expected ordinary expiration	2020
Patent status after ordinary expiration	No enforceable exclusionary right from an expired patent
Patent-term adjustment or extension	Must be confirmed in the USPTO patent record

The expiration analysis should use the official USPTO Patent Center record, including any terminal disclaimer, patent-term adjustment, reexamination certificate, or correction. A patent-term extension under 35 U.S.C. § 156 would generally be associated with regulatory approval of a qualifying drug product. This patent claims an inhaler device rather than an active drug, so a regulatory patent-term extension would not ordinarily be expected.

Is Patent 6,701,917 listed in the Orange Book?

Patent 6,701,917 is a device patent and does not claim an active ingredient, drug composition, or method of using a drug to treat a disease. It therefore would not ordinarily qualify for listing in FDA's Orange Book.

The Orange Book generally identifies patents submitted for approved drug products, including drug substance, drug product, and certain method-of-use patents. A mechanical inhaler patent may affect product freedom to operate without appearing in the Orange Book.

This distinction has several consequences:

It is not ordinarily an Orange Book patent for a drug product.
It does not itself create a Hatch-Waxman Paragraph IV filing pathway.
A generic applicant would not normally challenge it through an Orange Book certification.
Enforcement would generally proceed through ordinary patent litigation rather than an automatic 30-month stay tied to an Abbreviated New Drug Application.

FDA approval of an inhaler can still require device compatibility, dose uniformity, performance, and human-factors review. Those regulatory requirements are separate from patent rights. (U.S. Food and Drug Administration, 2024a, 2024b)

Are Paragraph IV challenges or biosimilar risks relevant?

A Paragraph IV challenge is not the principal risk profile for this patent. Paragraph IV certifications address listed patents associated with an approved drug product. Because Patent 6,701,917 claims inhaler mechanics, a competitor would generally address it through freedom-to-operate analysis and conventional patent litigation.

Biosimilar risk is not relevant. Biosimilars concern biological products and their manufacturing or clinical comparability. The patent does not claim a biologic, a biologic formulation, or a biologic manufacturing process.

The relevant competitors are:

Generic dry-powder inhaler manufacturers;
Combination-product developers;
Device-platform suppliers;
Contract inhaler manufacturers; and
Branded companies developing replacement inhalers.

What patent landscape surrounds the claimed technology?

The relevant landscape has several adjacent patent categories.

Dose-counter patents

These patents may cover:

Rotary dose counters;
Ratchet mechanisms;
Mechanical countdown displays;
Electronic dose sensors;
Optical or magnetic dose detection;
Dose-event authentication; and
Counter reset prevention.

Patent 6,701,917 is narrower than a broad counter concept because it requires a rolled ribbon, bobbin, spool, and tooth-and-pawl interaction.

Inhaler actuation patents

Separate patents may protect:

Lever or button actuation;
Breath-actuated release;
Cover-actuated preparation;
Airflow-triggered mechanisms;
Metering chambers; and
Reservoir refill or indexing systems.

A product can avoid Patent 6,701,917 and still infringe a different actuator or metering patent.

Formulation and manufacturing patents

The patent does not cover:

Dry-powder formulations;
Carrier particles;
Micronization;
Spray-drying;
Lactose blends;
Capsule filling;
Blister manufacture;
Device assembly; or
Inhaled treatment methods.

These rights can create separate barriers after the mechanical counter patent expires.

Delivery-system patents

Competing estates may cover:

Multi-dose reservoirs;
Unit-dose blisters;
Capsules;
Metering valves;
Powder deagglomeration;
Airflow channels;
Dose-loading structures; and
Reusable electronic adherence systems.

The commercial freedom-to-operate question therefore requires a family-level search across the complete inhaler, not just the dose counter.

What litigation and settlement issues should be reviewed?

Patent 6,701,917 should be searched in:

USPTO Patent Center;
PACER;
U.S. district court docket databases;
Federal Circuit opinions;
Patent Trial and Appeal Board records; and
International family records.

The key litigation questions are:

Whether the patent was asserted against an inhaler manufacturer.
Whether any claims were invalidated, amended, or disclaimed.
Whether a terminal disclaimer affected the term.
Whether any settlement included a license or field-of-use restriction.
Whether a related family member, continuation, or foreign counterpart remained in force.
Whether an accused product used a ribbon counter with a different trigger arrangement.

An expired patent generally cannot support a new infringement suit for post-expiration conduct. Historical litigation may still matter for damages, estoppel, construction of claim terms, and interpretation of related family patents.

How strong is the patent estate for commercial enforcement?

The patent's strongest technical position was against a specific mechanical architecture: a rolled ribbon transferred from bobbin to toothed spool by pawl engagement. Its weaknesses are structural specificity and the availability of alternative counter technologies.

Factor	Assessment
Claim breadth	Moderate for ribbon counters; narrow against electronic and disk counters
Technical specificity	High
Design-around availability	Material
Orange Book leverage	None expected
Paragraph IV leverage	None expected
Biosimilar relevance	None
Formulation coverage	None
Manufacturing coverage	Limited to claimed inhaler structure
Current exclusionary value	None after ordinary expiration
Historical licensing value	Potentially relevant for products using the claimed architecture

The patent had greater commercial value as part of an inhaler platform or licensing package than as a standalone drug patent. Its practical importance depended on whether a manufacturer used a physical ribbon counter and whether the counter was actuated by dose-meter movement or cover movement.

Key Takeaways

U.S. Patent 6,701,917 claims a mechanical inhaler dose counter using a bobbin, rolled ribbon, toothed spool, and pawl.
Claim 1 focuses on dose-meter-actuated spool rotation.
Claim 12 separately covers cover-actuated rotation through a transmission mechanism.
Claims 2, 3, and 14 address one-way rotation and reverse prevention.
Claims 4, 5, 8, and 11 cover visible numerical countdown arrangements.
Claims 9 and 10 narrow the system toward bulk dry-powder reservoirs.
The patent does not claim a drug substance, formulation, therapeutic method, or biologic.
It would not ordinarily be an Orange Book-listed patent or a Paragraph IV target.
Biosimilar risk is irrelevant.
The ordinary patent term appears to have ended in 2020, subject to the official USPTO term calculation.
Current commercial risk is more likely to arise from related inhaler, formulation, manufacturing, or delivery-system patents.

FAQs

Does Patent 6,701,917 cover electronic inhaler dose counters?

No. The claims require a physical rolled ribbon, bobbin, spool, and mechanical tooth-and-pawl interaction. A purely electronic counter would not ordinarily satisfy those limitations.

Does the patent cover blister-strip inhalers?

Not broadly. A blister inhaler could implicate the claims only if it also contains the claimed rolled ribbon and spool architecture. The patent does not generally cover blister packaging or blister indexing.

Can an expired inhaler patent block FDA approval?

No. FDA approval and patent enforceability are separate issues. An expired patent does not provide a current infringement barrier, although other unexpired patents may affect launch.

Does claim 12 require that cover movement correspond to dose delivery?

No. Claim 12 requires spool rotation when the cover moves between open and closed positions. It does not expressly require that cover movement itself dispense a dose.

What is the most important claim-construction issue?

The central issue is whether the accused counter has the claimed ribbon-transfer architecture: a rolled ribbon supported by a bobbin, a spool receiving the ribbon, and spool teeth engaged by a pawl or cover-operated transmission.

References

U.S. Patent No. 6,701,917, Medicament inhaler (issued Mar. 2, 2004). United States Patent and Trademark Office.
United States Code, 35 U.S.C. §§ 154, 271, 282, 283, 284, 285, and 156.
United States Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations. FDA.
United States Food and Drug Administration. (2024b). Reference product exclusivity and patent information in the Orange Book. FDA.
United States Patent and Trademark Office. (2024). Patent Center and patent term adjustment information. USPTO.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	028746	⤷ Start Trial
Argentina	028747	⤷ Start Trial
Argentina	064449	⤷ Start Trial
Austria	281861	⤷ Start Trial
Austria	415994	⤷ Start Trial
Austria	460955	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,701,917

Summary for Patent: 6,701,917